LAVU RATNAKAR sold $572K of ELV

LAVU RATNAKAR (EVP & Chief Digital Info Ofr) sold 1,300 shares of Elevance Health, Inc. (ELV) at $440.00 ($0.57M total) on 2026-11-05.

Original reporting
SEC EDGAR · LAVU RATNAKAR
Published Nov 6, 2026, 9:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 9:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ELV
Neutral
high confidence
Mentioned
$ELV
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ELVNeutralLow
01

Why it matters

The sale is a primary disclosure but modest in scale, likely resulting in limited market reaction.

02

Market read

A small insider sell by a senior executive; modest relevance for short-term traders.

03

What to watch

Potential upcoming personal liquidity needs or tax planning for the executive.

Relevance 5/10Novelty 4/10Timing: today

Background

Form 4 disclosures provide transparent insight into insider transactions, which can be used to gauge executive confidence.

Company-level read

Ticker impact

$ELVNeutralHigh confidence
Context

Executive Lavu Ratnakar sold 1,300 shares of Elevance Health for $572K, reducing his stake to 14,849 shares.

Expected impact

likely slight downward pressure as the market prices the insider sell.

Evidence & confidence

Form 4 filings are primary source; the transaction size is modest but notable for a C-suite executive.

Market effects

Minimal impact on the health insurance sector; insider sales are routine.

None

None

Counterpoint

The sale could be unrelated to company fundamentals; investors may ignore it.

Key entities

  • Lavu Ratnakar

    EVP & Chief Digital Info Officer at Elevance Health

  • Elevance Health, Inc.

    U.S.-listed health insurance and services provider (ticker ELV)

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ELVMed

The Perfect Child Sued by Elevance Health over $800M in Fraudulent Billing

Elevance Health (NYSE: ELV) sued The Perfect Child ABA and its founder, alleging $800M in fraudulent billing since 2021. The suit claims deceptive practices, inflated prices, and threats to patients' families. Elevance Health paid $160M to The Perfect Child ABA. The company is also facing a federal lawsuit by a parent for $363,816.17 in alleged surprise billing.

$CNCMed

Health insurers, hospitals rally after sweeping midterm win for Democrats

Shares of Medicaid-focused health insurers (Centene, Elevance, Molina) and hospital operators (HCA, Tenet, Universal) rose after Democrats won the midterms, raising hopes for sector-friendly policies. Analysts expect delays in Trump's OBBBA, easing pressure on Medicaid and ACA insurers, and potential extensions of enhanced subsidies. Year-to-date gains vary among companies.

$CVSMed

Aetna, Elevance, and Four Other Insurers Say the Medicare Advantage Star Rating System Is Broken — Now They Are Suing

CVS Health's Aetna subsidiary, along with Elevance Health, SCAN Health Plan, Alignment Healthcare, Healthfirst, and Centene, sued CMS over Medicare Advantage star ratings. They allege CMS used invalid measures, leading to lower ratings and $2B+ in lost bonus payments for Aetna. CMS has not responded. Ratings affect benefits for 4.2M Aetna members and $12.7B in annual bonuses.

Med

Elevance Earns $1.4 Billion Quarterly Profit as Membership Falls by 487,000 and Insurer Calls 2026 the Medicaid Trough

Elevance Health reported a $1.4B Q3 profit, up from $1.2B a year earlier, with 44.9M members, down 487K. The company expects 2026 to be the low point for Medicaid margins, with improvement in 2027. Elevance raised its full-year outlook to at least $29 per share, but is exiting some Medicaid markets and tightening spending. Medicaid work requirements begin in January 2027, potentially affecting 2.3M people.

$ELVMed

BofA raises Elevance stock price target to $500 on earnings beat

BofA Securities raised its price target for Elevance Health (ELV) to $500 from $480, citing a 10% Q3 earnings beat and raised 2026 guidance. The company's market cap is $94.2B, P/E ratio 19.62. BofA highlights seven 2027 tailwinds, including margin improvements and share buybacks. ELV reported Q3 EPS of $6.99 vs. $4.70 estimate, revenue of $50.4B vs. $49.32B estimate.